Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.

Détails

ID Serval
serval:BIB_75F2F83A31AE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
Périodique
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteur(s)
Jilek S., Mathias A., Canales M., Lysandropoulos A., Pantaleo G., Schluep M., Du Pasquier R.A.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Statut éditorial
Publié
Date de publication
06/2014
Peer-reviewed
Oui
Volume
20
Numéro
7
Pages
837-842
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To determine the long-term effect of natalizumab (NTZ) treatment on the expression of integrins and chemokine receptors involved in the migration of T cells towards the central nervous system (CNS).
We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment. We assessed the ex-vivo expression of phenotype markers (CCR7 and CD45RA), CNS-addressing integrins (CD11a, CD49d and CD29) and chemokine receptors (CXCR3 and CCR6) in CD4+ or CD8+ T-cell subsets by flow cytometry.
As compared to the pre-NTZ values, there was a marked increase in central memory (CCR7+/CD45RA-) CD4+ T cells and in effector memory (CCR7-/CD45RA-) CD8+ T cells at 12 and 24 months. In addition to an expected downregulation of both VLA-4 subunits (CD49d/CD29), we also found decreased T-cell expression of CXCR3 at 12 months, and of CD11a (LFA-1 αL subunit) at 12 months, but mostly at 24 months of NTZ treatment.
Our data show a nadir of CD11a expression at 2 years of NTZ treatment, at the peak of incidence of progressive multifocal leukoencephalopathy (PML), indirectly suggesting that a lack of these molecules may play a role in the onset of PML in NTZ-treated patients.

Mots-clé
Adverse effects, CD11a, CXCR3, LFA-1, T cell, VLA-4, cellular immunity, integrins, longitudinal study, natalizumab, progressive multifocal encephalopathy
Pubmed
Web of science
Création de la notice
27/07/2014 15:17
Dernière modification de la notice
20/08/2019 14:33
Données d'usage